# Actinium Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Actinium Pharmaceuticals, Inc.). ## Overview Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapeutics for cancer, with its core programs built around the alpha-emitting isotope Ac-225. Its lead assets include Actimab-A for myeloid malignancies, Iomab-B for conditioning before cell therapy or transplant, Iomab-ACT for CAR-T conditioning, and ATNM-400 for additional oncology applications. The company also has a proprietary manufacturing effort aimed at producing Ac-225 more efficiently through cyclotron-based methods. Actinium has not yet generated commercial product revenue and remains dependent on clinical progress, partnerships, grants, and capital markets funding. ## Products & services • Actimab-A targeted radiotherapeutic for AML and myeloid cancers • Iomab-B conditioning therapy for transplant/cell therapy settings • Iomab-ACT CD45-targeting conditioning program • ATNM-400 radiotherapeutic oncology program • Ac-225 cyclotron production technology • Clinical trial manufacturing and just-in-time radiopharmaceutical supply - **Clinical-stage radiotherapeutic drug candidates** (70%) — Investigational oncology therapies designed to deliver radioactive payloads to cancer targets such as CD33 and CD45. - **Conditioning and transplant-support programs** (15%) — Products intended to prepare patients for CAR-T therapy or stem cell transplant by depleting diseased or immune cells. - **Isotope manufacturing technology** (10%) — Cyclotron-based Ac-225 production methods and related know-how used to support internal programs and future supply. - **Collaborative research and grant-funded development** (5%) — NIH- and NCI-supported studies and partnered development work that help advance clinical programs. - Actimab-A targeted radiotherapeutic for AML and myeloid cancers - Iomab-B conditioning therapy for transplant/cell therapy settings - Iomab-ACT CD45-targeting conditioning program - ATNM-400 radiotherapeutic oncology program - Ac-225 cyclotron production technology - Clinical trial manufacturing and just-in-time radiopharmaceutical supply ## Customers Actinium's direct customers are not commercial end-users yet, because the company is still in clinical development and has no product sales. Its near-term stakeholders are hospitals, cancer centers, investigators, and clinical trial sites that administer its radiotherapeutic candidates under research protocols. The company also works with government and academic collaborators such as the National Cancer Institute, Memorial Sloan Kettering Cancer Center, and the NIH through grants and CRADAs. If approved, its eventual buyers would likely include oncology treatment centers, transplant programs, and commercial partners that can market and distribute the therapies in specific territories. - **Clinical trial hospitals and cancer centers** (primary) — They receive and administer Actimab-A, Iomab-B, and related investigational doses for oncology trials and early access studies. - **Academic and government research collaborators** (primary) — Institutions such as NCI and MSK support protocol development, clinical studies, and grant-funded research around conditioning and AML. - **Potential licensing and commercialization partners** (secondary) — Third parties with sales forces and distribution systems may commercialize approved products in selected territories. - **Future oncology treatment providers** (emerging) — If approved, hospitals and transplant centers would buy the therapies for AML, MDS, and cell-therapy conditioning use. - Cancer hospitals and trial sites administering radiotherapeutics in studies - Academic medical centers collaborating on conditioning and AML trials - Government research partners such as NCI and NIH-funded programs - Potential future commercial partners with sales and distribution infrastructure - Future oncology treatment centers and transplant programs if products are approved ## Geography Actinium is headquartered in the United States and its current operating footprint is centered on U.S.-based clinical development, manufacturing planning, and regulatory interactions. The company retains commercialization rights for Iomab-B in the U.S. and the rest of the world, while Immedica holds exclusive rights in certain EUMENA countries. Its clinical and research network includes major U.S. cancer hospitals and U.S. government collaborators, which makes domestic regulatory execution especially important. Internationally, the company has patent coverage in Canada, Europe, and Japan, and its future commercial model may rely on territory-by-territory partnering outside the U.S. - United States is the core base for R&D, trials, and planned manufacturing - U.S. commercialization rights are retained for Iomab-B - EUMENA rights for Iomab-B were licensed to Immedica - Clinical supply is delivered to large cancer hospitals, mainly in the U.S. - Patent coverage extends to Canada, Europe, and Japan - Future ex-U.S. growth may depend on regional partners and approvals ## Strategy Actinium's strategy is to advance a small number of differentiated radiotherapeutic programs through clinical proof-of-concept and then use partnerships to broaden development and commercialization. The company is trying to position Actimab-A as a backbone therapy in myeloid malignancies by combining it with chemotherapy, targeted agents, and cellular therapies. It is also building an internal Ac-225 manufacturing capability to reduce supply risk, lower cost, and support both current trials and future scale-up. In parallel, Actinium is using collaborations such as the NCI CRADA and the MSK work on Iomab-ACT to expand the clinical data package and increase partnering optionality. - **Advance Actimab-A clinical development** (short-term) — Actimab-A is the company's main value driver and needs clinical validation in AML and other myeloid malignancies. - **Build Ac-225 manufacturing capability** (medium-term) — In-house isotope supply can reduce cost, improve reliability, and support future clinical and commercial demand. - **Expand partnering and territory-based commercialization** (medium-term) — The company lacks a commercial sales infrastructure and may need partners to monetize approved products efficiently. - Advance Actimab-A through Phase 2/3 development in AML - Use combination regimens to broaden the addressable market - Develop Iomab-ACT with NCI and MSK to support CAR-T conditioning - Build in-house Ac-225 manufacturing to improve supply control - Pursue partnerships for commercialization in selected territories - Leverage patent estate to protect isotope production and product use ## Risks Actinium is a clinical-stage company with no commercial product revenue, so its business depends on successful trial outcomes, regulatory approvals, and financing access. Development risk is high because radiotherapeutics are complex to manufacture, ship, and administer, and the company relies on short-lived isotopes that must be delivered just in time. Regulatory delays, including FDA or NIH disruptions and government shutdowns, can slow trials and grant-funded work, while competition from other biotech and pharma companies may reduce partnering or commercialization opportunities. The company also faces patent uncertainty, hazardous-material handling risk, and execution risk around building its own Ac-225 manufacturing capability and retaining specialized personnel. - **Clinical development failure** [critical] — Actimab-A, Iomab-B, Iomab-ACT, and ATNM-400 are investigational and may not show sufficient efficacy or safety. - **Regulatory delays and agency disruption** [high] — FDA, NIH, and other government actions can slow trial starts, reviews, and grant activity. - **Financing dependence** [high] — The company has no product revenue and has historically funded operations through equity issuance and grants. - **Manufacturing and isotope supply risk** [high] — Radiotherapeutics require reliable Ac-225 production and just-in-time delivery to hospitals. - **Competitive pressure** [medium] — Other biotech and pharmaceutical companies are developing competing oncology and radiopharmaceutical programs. - **Hazardous materials and safety liability** [medium] — Radioactive and biological materials increase compliance burden and potential liability. - No commercial sales yet, so value depends on clinical and regulatory success - Radiopharmaceutical supply is fragile because isotopes decay quickly - FDA, NIH, and other agency disruptions can delay trials and grants - Competition in oncology and radiotherapeutics may limit market access - Patent disputes or weak IP protection could reduce exclusivity - Hazardous radioactive materials create safety, compliance, and liability risk - Capital needs remain significant until commercialization or partnering ## Accounting Actinium currently records no commercial revenue, so reported results are driven mainly by research and development spending, grant revenue, and financing activities. The NIH STTR grant tied to the MSK collaboration is an example of other revenue that depends on reimbursable research activity rather than product sales, which can create quarter-to-quarter variability. The company also recognized a large upfront non-refundable payment from Immedica in 2022 under the Iomab-B license agreement, and future milestone and royalty accounting will depend on regulatory and commercial events. Because the business is pre-commercial and capital intensive, investors should also watch share issuance, stock-based compensation, and any future impairment or valuation judgments tied to intangible assets, patents, or development programs. - **Grant revenue recognition** — Can create uneven other revenue and margin presentation - **License and milestone accounting** — Revenue timing depends on regulatory and commercial achievements - **Equity financing and dilution** — Affects share count, cash runway, and per-share metrics - **R&D expense timing** — Quarterly operating loss can swing with trial activity - No commercial revenue means results are dominated by R&D and grant activity - Grant revenue can fluctuate with reimbursable project timing and milestones - License upfront payments and future milestones affect revenue recognition timing - Royalty accounting will depend on future partner sales in licensed territories - Stock issuance and equity financing affect per-share dilution and cash runway - Development-stage assets and patents may require impairment or valuation review --- *Last updated: 2026-08-11T04:46:19.406643+00:00*